Thompson Davis & CO. Inc. Purchases Shares of 1,237 Danaher Corporation $DHR

by · The Cerbat Gem

Thompson Davis & CO. Inc. acquired a new position in Danaher Corporation (NYSE:DHR – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,237 shares of the conglomerate’s stock, valued at approximately $244,000.

Several other institutional investors and hedge funds also recently made changes to their positions in DHR. Red Tortoise LLC lifted its stake in Danaher by 175.0% in the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after buying an additional 98 shares during the period. Costello Asset Management INC acquired a new position in shares of Danaher during the 1st quarter valued at $41,000. Ramirez Asset Management Inc. bought a new position in Danaher during the second quarter worth $40,000. Mowery & Schoenfeld Wealth Management LLC grew its holdings in Danaher by 53.8% in the first quarter. Mowery & Schoenfeld Wealth Management LLC now owns 203 shares of the conglomerate’s stock worth $42,000 after purchasing an additional 71 shares during the period. Finally, Strengthening Families & Communities LLC increased its stake in Danaher by 81.4% in the first quarter. Strengthening Families & Communities LLC now owns 254 shares of the conglomerate’s stock valued at $52,000 after purchasing an additional 114 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Activity

In other Danaher news, Director Teri List sold 2,778 shares of Danaher stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the sale, the senior vice president owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 29,728 shares of company stock valued at $6,448,990 in the last ninety days. 11.20% of the stock is currently owned by insiders.

Danaher Price Performance

Shares of NYSE:DHR opened at $221.50 on Friday. The stock’s fifty day simple moving average is $205.21 and its two-hundred day simple moving average is $200.91. The stock has a market cap of $156.46 billion, a PE ratio of 45.67, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $258.23.

Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same period in the previous year, the company earned $1.71 earnings per share. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. As a group, analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s dividend payout ratio (DPR) is presently 26.39%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on DHR. Guggenheim reissued a “buy” rating and set a $250.00 price objective on shares of Danaher in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft boosted their price objective on Danaher from $235.00 to $250.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Barclays increased their target price on Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. JPMorgan Chase & Co. boosted their price target on shares of Danaher from $260.00 to $270.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Finally, Rothschild & Co Redburn reaffirmed a “neutral” rating and issued a $220.00 price objective (down from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Eighteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $243.39.

Check Out Our Latest Analysis on Danaher

About Danaher

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Recommended Stories